Baiaotai (688177.SH) issued a forecast loss. The net loss for half a year is expected to be 230 million yuan to 290 million yuan

According to the Zhitong Finance App, Biotai (688177.SH) announced that the company expects to achieve a loss of 230 million yuan to 290 million yuan in net profit attributable to the owner of the parent company for the first half year of 2026, an increase of 105 million yuan to 165 million yuan in losses over the same period last year.

The company actively expanded its market, and sales of adalimumab injection (Geleride®) and tocilizumab injection (Schrelli®) injections increased steadily compared to the same period last year. Many R&D projects such as BAT8006 and BAT3306 are in the critical clinical phase, and R&D investment has increased significantly. The increase in expenses was greater than the increase in operating income, which led to an increase in losses.